drugset / Trial / NCT07002476

Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion

NCT07002476

Phase 3 Recruiting 652 enrolled Shanghai East Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

A prospective, multicenter, open-label, randomized controlled study to assess the effects of early intensive lipid-lowering initiated before endovascular treatment setting on (i) functional outcome in patients with acute ischemic stroke between preoperative intensive lipid-lowering therapy with PCSK9 inhibitor (PCSK9i) and guideline-recommended standard of care (SoC)(ii) safety in these patients.

Timeline

Start
2025-06-19
Primary completion
2028-06-01
Completion
2029-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Recaticimab Monoclonal antibody 450 mg Subcutaneous

Indications